T
he subcutaneous (S)-implantable cardioverter defibrillator (ICD) (Boston Scientific) is an entirely subcutaneous system that does not require intraprocedural vascular access or endovascular defibrillator leads or coils.
1 The S-ICD has a novel mechanism of defibrillation and is associated with an increased energy requirement for defibrillation when compared with traditional transvenous ICDs.
1 These factors, in association with an absence of data on the safety of forgoing ventricular fibrillation (VF) conversion testing at the time of implant, have made VF conversion testing at the time of S-ICD implant a class I (level of evidence C) recommendation. 2 This is in stark contrast to the recommended approach for defibrillation threshold testing (DFT) at the time of transvenous ICD implant, where testing is not required routinely and is typically reserved for those at higher risk for inadequate safety margins (ISMs). 2 Prior research from the National Cardiovascular Data Registry (NCDR) ICD Registry has demonstrated a compelling need for additional research on VF conversion testing at the time of S-ICD implantation based on very high rates of successful VF conversion testing at the time of S-ICD implant (92.7% and 99.8% at ≤65J and ≤80J, respectively), declining adherence to the class I recommendation for use of VF conversion testing at the time of S-ICD implant, and increased incidence of periprocedural cardiac arrest among recipients of S-ICDs (compared with recipients of transvenous ICDs), which could be related to VF conversion testing. 3 Based on these knowledge gaps regarding VF conversion testing after S-ICD implantation, we performed an analysis of the NCDR ICD Registry to understand factors associated with the use of VF conversion testing, predictors of ISM at the time of VF conversion testing, and inhospital outcomes associated with VF conversion testing.
METHODS
The data, analytic methods, and study materials cannot be made available to other researchers by the authors for purposes of reproducing the results or replicating the procedure because the data are owned by the NCDR. The Yale University Human Investigation Committee approved the present analysis with waiver of informed consent.
Patient Characteristics
Baseline characteristics were obtained from the ICD Registry V2.1 data collection form and included demographics, history and risk factors, diagnostic studies, and relevant preprocedure hospitalization data. We considered all patients who underwent S-ICD implantation between September 28, 2012, the date of the US Food and Drug Administration approval, and April 1, 2016, the date at which the NCDR transitioned to an updated case report form that did not include information on VF conversion testing. For the first aim (predicting use of VF conversion testing), we excluded patients who underwent S-ICD generator replacement, reportedly underwent upper limit of vulnerability testing (which is not feasible with the S-ICD), and those implanted outside of the United States. For the second aim (predictors of ISM), we included the subset of the aim 1 patients who underwent VF conversion testing and additionally excluded those with a reported VF conversion testing result outside of the plausible range (<10J or >80J) and those with a prior ICD (or missing information regarding history of a prior ICD). For the third aim (inhospital outcomes), we included the subset of patients from the first aim who were admitted for the S-ICD procedure and excluded those with a prior ICD (or missing information regarding history of a prior ICD).
Predictors of Interest
We considered several variables for the multivariable models, including demographics (age, sex, ethnicity, and race), anthropometric variables (height, weight, body mass index [BMI] , and body surface area [BSA]), hospital characteristics, and past medical history. Glomerular filtration rate was calculated using the Modification of Diet in Renal Disease formula. 4 Implausible clinical values for continuous variables were set to missing before the start of the analysis and later imputed. Both missing continuous variables and categorical variables were imputed using fully conditional specification before modeling.
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Clinical Perspective What Is New?
• This study demonstrated that use versus nonuse of ventricular fibrillation conversion testing after subcutaneous implantable cardioverter defibrillator (S-ICD) implantation in the United States is more related to physician preference than patient characteristics.
• This study identified several patient characteristics associated with an insufficient defibrillation safety margin among recipients of S-ICDs, including increased body mass index, severely decreased ejection fraction, white race, and ventricular pacing on the preimplantation ECG.
• Use of ventricular fibrillation conversion testing after S-ICD implantation was not associated with a composite of in-hospital complications or death.
What Are the Clinical Implications?
• An understanding of risk for insufficient defibrillation safety margin after S-ICD implant may be useful for ICD selection (transvenous versus subcutaneous) and a targeted approach for the use of ventricular fibrillation conversion testing.
• Ventricular fibrillation conversion testing after S-ICD implantation does not appear to be associated with excess risk of adverse events in properly selected patients.
Circulation. 
Outcomes
All outcomes were ascertained from the NCDR ICD Registry case report form. For the first aim, which sought to identify predictors of use of VF conversion testing after S-ICD implantation, the outcome of interest was use of VF conversion testing as reported in the case report form. For the second aim, ISM was defined as when the lowest energy that resulted in conversion of ventricular fibrillation was >65J during the procedure. This definition was based on the widely held belief that a successful conversion at 65J represents an adequate safety margin relative to 80J, which is the only programmable output used outside of testing in the electrophysiology laboratory. Device revision because of an ISM may have been performed before the lowest achieved VF conversion energy; therefore, the VF conversion value for this study best reflects the VF conversion energy at the final device position. The ICD Registry does not contain data regarding whether multiple tests were performed and whether device revisions were required to achieve the lowest reported value; as such, data on the frequency and outcomes associated with multiple testing and device revisions cannot be presented. For the third aim, the primary end point was a composite of inhospital adverse events consisting of death, cardiac arrest, cardiac perforation, valve injury, hematoma requiring reoperation or blood transfusion, hemothorax, infection, lead dislodgement, myocardial infarction, pericardial tamponade, set screw problem, pneumothorax, transient ischemic attack or stroke, or urgent cardiac surgery.
Statistical Analysis
Aim 1: Predictors of Use of VF Conversion Testing
We described the characteristics of patients, centers, and physicians associated with use versus nonuse of VF conversion testing. Between-group differences were tested using the χ-square test for categorical variables and the Wilcoxon rank sum tests or t tests for continuous variables. We used multivariable logistic regression using generalized estimating equations accounting for clustering within facilities. Purposeful selection (as described by Hosmer et al 6 ) was used for patientlevel model selection. All variables in Table 1 were considered for inclusion except for year of implantation and giant cell myocarditis (n=1, precluding ability to generate an estimate). When a nonlinear relationship between a continuous variable and use/nonuse of VF conversion testing was observed, we plotted the relationship and binned the variable based on the observed relationship using clinically relevant thresholds. Generalized linear mixed models and hospital-specific median odds ratios 7 were later used to ascertain facility specific effects.
Aim 2: Predictors of ISM
We described the characteristics of patients, centers, and physicians associated with sufficient versus ISM after S-ICD implantation. Between-group differences and nonlinear continuous variables were handled as per aim 1. We created patient-level multivariable logistic regression models (using generalized estimating equations to account for clustering within facility) to identify independent predictors of an ISM at VF conversion testing. We considered all variables from aim 1 after additionally excluding several variables with low prevalence: amyloidosis, Epstein's anomaly, transposition of the great vessels, common ventricle, and short QT syndrome. β-coefficients derived from the model were subsequently used to generate a weighted risk score.
We included sensitivity analyses assessing the association between use of amiodarone and sotalol at time of discharge and ISM, given the known impact of these drugs on the defibrillation threshold of transvenous ICDs. These variables were not considered in the main model because the case report form only collects discharge medication, and it is possible that these medications could have been started or stopped after VF conversion testing.
Aim 3: The Association Between VF Conversion Testing and In-Hospital Events
To determine the risk-adjusted association between use of VF conversion testing and in-hospital outcomes, we utilized generalized boosted models to calculate inverse probability of treatment weights. 8, 9 For each model, generalized boosted models fit a piecewise constant model to predict the probability of VF conversion testing. The model consists of many simple regression trees iteratively combined to create an overall piecewise constant function. The generalized boosted models were fitted iteratively until the imbalance between groups was minimized. For our models, we set the maximum number of trees to be 20 000 and restricted interactions to 2 levels. Balance between groups was assessed using weighted standardized differences, with values <10% being considered sufficiently balanced. 10, 11 We calculated weighted average treatment effects for each outcome defined earlier using weighted logistic regression with the outcome of interest as the dependent variable and VF conversion testing as the independent variable. Comparisons were summarized using odds ratios (ORs) with 95% confidence interval (CI).
Analyses were performed using SAS (Version 9.4, SAS institute) and R (Version 3.4.0, R Foundation for Statistical Computing).
RESULTS
Predictors of Use of VF Conversion Testing
A total of 8190 patients underwent S-ICD implantation between September 28, 2012, and April 1, 2016. After excluding 60 patients who underwent S-ICD generator replacement, 169 patients who reportedly underwent upper limit of vulnerability testing (which is not possible with the S-ICD), and 1 patient who was implanted outside the United States, 7960 patients remained for analysis ( Figure 1 ). Of these patients, 5624 (70.7%) underwent VF conversion testing. The baseline characteristics of patients who did and did not undergo VF conversion testing are depicted in Table 1 .
In logistic regression analyses, deferral of VF conversion testing was independently associated with several patient characteristics (Table 2) , including increased BMI, increased BSA, severely reduced ejection frac-
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tion (<20%), dialysis dependence, warfarin use, and anemia. VF conversion testing was more common in patients with prior coronary artery bypass grafting, hypertrophic cardiomyopathy, and implant at a public hospital.
The area under the curve for the generalized linear mixed model that incorporated a facility-specific effect was substantially greater than that for the patient-level model only accounting for facility clustering (0.877 versus 0.619), and the hospital-specific median OR was 5.16, demonstrating that facility preference is a major determinant of VF conversion testing.
Predictors of ISM
For this analysis, we additionally excluded patients with an improbable VF conversion testing value (n=56) or a prior ICD (or missing data regarding prior ICD) (n=704). Of the resulting 4864 patients, 336 (6.9%) were found to have an ISM; all patients had successful VF conversion at ≤80J. The baseline characteristics of patients who did and did not have ISM at time of VF conversion testing are depicted in Table 3 . Two of the patients with an ISM required a separate procedure (during the index hospitalization) to revise the S-ICD.
ISM was more common among white patients and those with ventricular pacing on the preimplant ECG, higher preimplant blood pressure, larger BSA, higher BMI, and lower ejection fraction (Table 4) . Prior coronary artery bypass grafting was associated with a lower likelihood of ISM. There was no association between ISM and age, sex, New York Heart Association class, history of cardiac arrest, hypertrophic cardiomyopathy, or dialysis status. The area under the curve for the adjusted model was 0.679. A risk score was able to identify patients at low (<5% for scores 0-9), medium (5% to 10% for scores [10] [11] [12] [13] [14] [15] [16] , and high (>10% for scores ≥17) risk for ISM ( Figure 2 ). Table I in the online-only Data Supplement details how the risk score was calculated for each patient.
We performed sensitivity analyses to assess the association between discharge amiodarone (n=319) and sotalol (n=31) and an ISM. In a series of adjusted models, we observed no association between either amiodarone (OR, 1.36; 95% CI, 0.91-2.04; P=0.13) or sotalol (OR, 1.57; 95% CI, 0.50-4.97; P=0.44) and an ISM.
In-Hospital Outcomes and Use Versus Nonuse of VF Conversion Testing
In an inverse probability weighted cohort, the rate of in-hospital complications was low overall, and there was no significant difference among those who did (0.84%) and did not (1.16%) undergo VF conversion testing (OR, 0.72; 95% CI, 0.47-1.09; P=0.11; reference group = no VF conversion testing; Table 5 ). Table  II in the online-only Data Supplement depicts the study cohort before and after inverse probability weight- DFT testing was performed routinely after transvenous ICD implant for years to ensure an adequate safety margin (usually 10J) between DFT and the maximum device output. As the maximum device output increased and the defibrillation technology evolved over time, the perceived need to perform DFT testing declined, leading to a pivotal trial that confirmed that routine DFT testing was indeed not necessary for most patients with a primary prevention transvenous ICD. 12 On average, the S-ICD has a DFT that is about 3x higher (and somewhat more variable) compared with a transvenous ICD (36.6±19.8J versus 11.1±8.5J).
1 The volume of subcutaneous fat between the defibrillator coil and chest wall, 13 as well as position of the coil and pulse generator, 1,13 have been identified as important factors in achieving optimal DFTs with S-ICDs. Accordingly, the maximum (and only) programmable output for the S-ICD is 80J, compared with ≈35-40J for transvenous ICDs. Although early S-ICD studies suggested high rates of successful conversion of VF, 1,14,15 there remained a relative paucity of data on rates of successful defibrillation and no data on whether it was safe to forgo VF conversion testing after S-ICD implantation. Thus, the expert consensus statement on ICD programming that was published after the approval of the S-ICD recommended VF conversion testing after S-ICD implantation as a class I recommendation based solely on expert consensus. 2 Despite a class I recommendation, the use of VF conversion testing after S-ICD implantation has been declining in the United States, from 82.4% to 71.4% between 2012 and 2015. 3 The present study aimed to determine factors associated with VF conversion testing. We found that nonuse of VF conversion testing was more common among patients who may have been at higher perceived risk for VF conversion testing complications (patients with increased BMI/BSA, severely reduced left ventricular EF, dialysis dependence, and oral anticoagulation). The adjusted model that incor- The area under the curve for the patient level model is 0.619, compared with 0.877 for the generalized linear mixed model. The hospital specific median odds ratio represents the median value of the odds ratio generated by comparing the rates of ventricular fibrillation conversion testing in 2 randomly selected hospitals. 7 The hospital-specific median odds ratio for use of ventricular fibrillation conversion was 5.16, emphasizing that facility preference is a strong factor in determining use vs nonuse of ventricular fibrillation conversion testing.
*Odds ratio should be interpreted as the odds of not undergoing ventricular fibrillation conversion testing. porated the site effects was more robust with an area under the curve of 0.877 (versus 0.619 for the model with patient factors only), demonstrating that site factors appear proportionally more important than patient factors. Given the limits of registry data, we are unable to determine why facility preference is such a strong predictor of use of VF conversion testing, although it is plausible that cumulative experience regarding strategies that address ISM has decreased the perceived need for compulsory testing. An ISM after S-ICD implantation appears to be uncommon. In our study, 6.9% of patients did not have successful VF conversion at ≤65J, although all had successful VF conversion at ≤80J. These results are consistent with those reported from the EFFORTLESS S-ICD registry (Evaluation of Factors Impacting Clinical Outcome and Cost Effectiveness of the S-ICD). An early report 16 from this registry indicated that 95% of patients had successful VF conversion at ≤65J, and a more contemporary report with approximately twice as many patients reported this rate was 91.6%. 17 Although there are several well-established predictors of an ISM among transvenous ICDs, 18 limited data exist for the S-ICD. A recently published report from the S-ICD PAS (Post Approval Study) showed that among the 1412 patients who underwent conversion testing, 95.6% of first shocks were successful at the final device position. 19 Prior transvenous ICD extraction, increased height, and increased BMI were independently associated with first shock failure, whereas black race was associated with first shock success. 19 These findings are concordant with some of our findings that white race and increased BMI were associated with an ISM at the time of VF conversion testing. In contrast to our study, the PAS did not identify a reduced EF (handled as a continuous variable) as a predictor of first shock failure.
Based on recent computer modeling emphasizing the impact of subcutaneous fat on DFTs with the S-ICD, 13 it is not surprising that increased BMI and BSA were both independent predictors of an ISM in the current analysis. It is important to note that BSA was not considered in the S-ICD PAS predictive model. In our study, height was collinear with and less predictive than BSA and therefore was not in the final model. It is notable that BMI and BSA are not usually associated with ISM in transvenous systems.
There are several other notable differences in predictors of ISM among patients with S-ICD versus transvenous ICD. Dialysis-dependent chronic kidney disease has been linked to ISM with transvenous ICDs but was not associated with an ISM in our study of S-ICDs. This finding is clinically relevant because the absence of endovascular leads has been hypothesized to be particularly beneficial among patients on dialysis who are at a high risk for intravascular infections and dialysis access complications. Decreased age (<70 years), Hispanic ethnicity, and secondary prevention ICD indication have been associated with ISM among transvenous patients with an ICD 18 but were not associated with ISM after S-ICD implantation. Thus, predictors of ISM vary by device type. These characteristics could be considered when selecting an ICD system or applying a targeted approach to VF conversion testing.
After inverse probability weighting, VF conversion testing was not associated with a significant increase in the risk of any inhospital complication reported to the NCDR. These results are consistent with the use of DFT in appropriately selected patients with transvenous ICDs. 12 The rate of cardiac arrest was lower among patients who underwent VF conversion testing. Although it is plausible that VF conversion testing resulted in a higher likelihood of successful conversion 
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of spontaneous ventricular tachycardia or fibrillation in the hospital after S-ICD implantation, precluding the need for cardiopulmonary resuscitation and external defibrillation, it is more likely that intraprocedural cardiac arrests decreased the likelihood of performing VF conversion testing at the conclusion of the implant. However, these hypotheses are not possible to test because the ICD Registry case report form does not specify whether a periprocedural cardiac arrest occurred during or after the ICD procedure. These results should be confirmed in an adequately powered prospective randomized trial.
Limitations
This study has several important limitations. This study was observational and retrospective in nature, and the use of VF conversion testing was not randomized. As with all registry studies, data may be prone to more inaccuracies and underreporting of complications when compared with randomized trials. However, prior analyses have suggested >90% accuracy for data fields. 20 The VF conversion value used for this analysis represents the lowest value during the procedure, which could have been achieved after an ISM led to an inlaboratory device revision, followed by repeat induction and testing. Thus, the data on rates and predictors of ISM best reflect the final device position. The ICD Registry case report form does not collect data on whether a device revision or reprogramming occurred during the initial procedure; as such, we are unable to report on the use of intraprocedural strategies to mitigate ISM. There were insufficient patients in this study to use separate derivation and validation cohorts when designing a model to predict ISM. The relatively small number of patients on amiodarone or sotalol may have reduced the power to detect an association between use of these drugs and an ISM. We did not have data on several potentially important predictors of an ISM, including electrode and pulse generator location, 1,13 chest wall dimensions, cardiac dimensions, 21 and amount of subcutaneous fat below the electrode and pulse generator. 13 Although the inverse probability cohort appeared well balanced based on assessment of standardized differences, we cannot rule out the possibility of residual confounding, which would most likely lead to an underestimate of risk associated with VF conversion testing. 22 Inhospital complications were relatively infrequent, limiting the statistical power to detect a difference among patients who did and did not undergo VF conversion testing. We did not have longitudinal outcomes, which are necessary to determine whether VF conversion testing is able to improve clinical outcomes by way of improving defibrillation of spontaneous ventricular arrhythmias. Last, the analysis of inhospital complications included only patients implanted during an elective hospitalization, potentially limiting generalizability to patients implanted during a hospitalization for another reason (eg, heart failure exacerbation).
Clinical Implications
This study has several clinically relevant implications. Although facility preference appears to be the dominant factor regarding the decision to perform VF conversion testing, several of the patient characteristics associated with nonuse of VF conversion testing were also associated with risk for an ISM (eg, BSA, BMI, and severely reduced left ventricular EF). This finding suggests that the patients who may be most poised to benefit from VF conversion testing are less likely to undergo the procedure. This could potentially be related to greater perceived risk of performing DFT in these patients. The risk for ISM after S-ICD implantation can be predicted with moderate accuracy using several readily available clinical variables. Understanding risk for ISM has the potential to lead to a targeted approach to VF conversion testing, as well as improve ICD system selection. For example, our study results suggest that, when compared with a transvenous ICD, the S-ICD may be associated with a more favorable safety margin among several patient groups, including patients on dialysis, blacks, Hispanics, younger patients, and men. In contrast, the S-ICD, when compared with the transvenous ICD, appears to be associated with a less favorable safety margin among patients with an increased BMI and increased BSA. Although the present study suggests that VF conversion testing may be safe in most patients after S-ICD implantation, there are several patient groups to which the results should not be generalized, including patients with a severely reduced left ventricular EF, unrevascularized coronary artery disease, or an intracardiac thrombus.
CONCLUSIONS
Although the use of VF conversion testing after S-ICD implantation is associated with several patient characteristics, facility preference appears to have a greater overall influence on use of testing. An ISM is relatively infrequent after S-ICD implantation and is associated with several clinical variables. VF conversion testing was not associated with increased inhospital complications or death. The results from this study have important im- 
